Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom.
David Zaccardelli
PricewaterhouseCoopers LLP
--
79
Market Capitalization
2.46B
Enterprise Value
2.18B
Enterprise Value/EBITDA
-16.79
Price to Earnings Ratio
--
Price to Sales
--
Price to Book
13.97
Price to Cash
--
Gross Margin
0.00%
Operating Margin
--
Profit Margin
0.00%
Return on Equity
-55.38%
Return on Invested Capital
-43.75%
Return on Assets
-37.88%
Revenue (ttm)
0.00
Revenue Per Share (ttm)
0.00
Gross Profit (ttm)
0.00
EBITDA (ttm)
-130.01M
Net Income Available to Common (ttm)
-125.45M
Diluted EPS (ttm)
-0.77
Beta (5Y Monthly)
0.44
52-Week Change
97.53%
S&P 500 52-Week Change
34.41%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding
81.24M
Dividend Yield
0.00%
Float
76.94M
Percent Held by Insiders
4.80%
Percent Held by Institutions
85.88%
Total Cash (mrq)
404.60M
Total Cash Per Share (mrq)
4.98
Total Debt (mrq)
122.20M
Total Debt/Equity (mrq)
72.62%
Current Ratio (mrq)
8.61%
Quick Ratio (mrq)
8.61%
Book Value Per Share (mrq)
2.02
Operating Cash Flow Per Share (ytd)
-0.38
Free Cash Flow (ytd)
-30.76M
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
